# NJEDA

> NJEDA is a VC fund in Newark backing Health Care and Biotechnology. See 142 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Newark, United States
- Total investments: 142
- Last investment: Jul 2026
- Lead investor: 89%
- Last fund: Aug 2017
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/njeda/about/
- X (Twitter): https://twitter.com/newjerseyeda
- Website: https://www.njeda.com/
- Facebook: https://www.facebook.com/NewJerseyEDA/

NJEDA is a government entity assisting and giving access to capital, including tax-exempt and taxable bond financing. It also offers loans, loan guarantees, and business and tax incentives. In addition, it offers real estate development assistance and technology facilities. In 1974, John Smith established it in Trenton, New Jersey.

## Contacts

5 contacts available for NJEDA. Shizune tracks 12 team members at NJEDA. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/brennan-candito-corp?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 20 | 14% |
| Biotechnology | 15 | 11% |
| Medical | 12 | 8% |
| Information Technology | 10 | 7% |
| Software | 9 | 6% |

140 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Grant | 89 | 63% |
| Seed | 7 | 5% |
| Funding Round | 4 | 3% |
| Venture - Series Unknown | 4 | 3% |
| Series A | 3 | 2% |

8 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 98 | 69% |
| Trinidad and Tobago | 2 | 1% |
| Israel | 1 | 1% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Frederick J. Cole | Senior Vice President- Operations | 0 | https://shizune.co/investors/profile/frederick-j-cole |
| Lori Matheus | Senior Vice President- Finance & Development | 0 | https://shizune.co/investors/profile/lori-matheus |
| Debbie Hart | Chair at the Commission on Science, Innovation and Technology (CSIT) | 12 | https://shizune.co/investors/profile/debbie-hart-6196 |
| Emma Corrado | Deputy Chief Operating Officer | 0 | https://shizune.co/investors/profile/emma-corrado |
| Evan Weiss | President and CEO | 0 | https://shizune.co/investors/profile/evan-weiss-1367 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Hill Research | We develops software for clinical trial operations. Its platform, TriClick, uses AI agents to assist with tasks such as data anonymization, protocol design, and patient recruitment. The tools extract information from medical records, generate standardized reports, and organize content for regulatory submissions. They integrate with clinical datasystems and follow data privacy requirements. The company’s team includes professionals in artificial intelligence and clinical research. |  | Venture - Series Unknown | Jul 01, 2026 |  |
| CardioLink Technologies | CardioLink AI uses AI to improve cardiac patient care. Their platform automates ECG analysis and identifies high-risk cardiovascular conditions early, helping doctors make faster, more accurate diagnoses. By streamlining clinical workflows and providing real-time insights, they aim to reduce hospital readmissions and improve patient outcomesthrough advanced, data-driven heart monitoring. |  | Grant | Apr 07, 2026 |  |
| AIntropy | AIntropy develops "Universal Knowledge Perception" technology, enabling AI to retrieve and understand information from multi-modal sources like video, visual data, and databases. This platform supports high-value applications, including real-time sales copilots and pharmaceutical compliance |  | Grant | Apr 06, 2026 |  |
| AgentGov | AgentGov provides an AI-powered fraud detection platform designed for government, utilizing advanced algorithms to identify anomalies and generate court-ready evidence |  | Grant | Apr 06, 2026 |  |
| DevPlus | DevPlus is an AI-agent infrastructure management with embedded compliance |  | Grant | Apr 06, 2026 |  |
| GlucoSync | GlucoSync is a real-time AI decision support for diabetes treatment |  | Grant | Apr 06, 2026 |  |
| Hydronos Labs | Hydronos Labs is the “Weather Underground” for near-term weather and climate hazard risk - a broadly available, scientifically credible platform, providing a continuously improving underlying data and software layer. Founded by lead scientist Colby Fisher PhD and Princeton Executive-in-Residence Joseph Studholme in 2020, Hydronos has built anext-generation “insights-as-a-service” platform - superior in cost, transparency and ease of use. Successful POCs from the platform include flood history underwriting, disaster emergency response, and wildfire risk to inventory/pricing/delivery for a national supermarket retail supply chain.In September 2024, Hydronos was selected (14 companies out of 700+) for the prestigious NJ FAST Plug&Play accelerator program.This is an ‘‘Open Core” product model: leveraging a robust research user community to improve and monetize current and future edges in data/model quality - through AI, machine learning, and knowledge graph powered software products provided via a freemium model. Our goal is to establish Hydronos Labs as the primary “open” provider of this layer in the risk transfer financial ecosystem - as the branded, trusted, broadly available, reasonably priced global data platform for commercially actionable climate intelligence. From a broad user base, we build credibility, a customer-driven development cycle and a brand that will enable proven monetization strategies at scale, including marketing to qualified users of mitigation and insurance partner solutions for their identified risks. |  | Grant | Apr 06, 2026 |  |
| Scholera | Scholera is an adaptive, predictive learning intelligence platform |  | Grant | Apr 06, 2026 |  |
| Citius Pharmaceuticals | Citius Pharmaceuticals is a biopharmaceutical company that develops and commercializes therapeutic products for large and growing markets. Citius products offer new and expanded indications for previously approved pharmaceutical products as a means to achieve market position or market exclusivity. By using previously approved drugs withsubstantial safety and efficacy data, Citius seeks to reduce the risks associated with pharmaceutical product development.Citius is advancing two proprietary product candidates, our Mino-Lok™ product and a Hydrocortisone-Lidocaine formulation. Citius believes the markets for its products are large and underserved by the current standard of care. | $3.8M | Grant | Feb 24, 2026 |  |
| Synchrony Medical | Synchrony Medical is a clinical stage medical device company developing LibAirty, a next generation, home-use, airway clearance system designed to help patients with chronic lung disease such as COPD and CF maintain clear lungs with a short, daily, proficient treatment. | $5M | Venture - Series Unknown | Feb 18, 2026 |  |

10 of 142 investments shown.

## Co-investors
- [Commission on Science, Innovation and Technology](https://shizune.co/investors/profile/commission-on-science-innovation-and-technology) — VC Fund, 12 deals together
- [New Jersey Economic Development Authority](https://shizune.co/investors/profile/new-jersey-economic-development-authority) — VC Fund, 3 deals together
- [SOSV HAX](https://shizune.co/investors/profile/hax-accelerator) — VC Fund, 2 deals together
- [Broadfin Capital](https://shizune.co/investors/profile/broadfin-capital) — VC Fund, 1 deal together
- [Cabinet Office - GOV.UK](https://shizune.co/investors/profile/cabinet-office) — VC Fund, 1 deal together
- [Cleantech Open](https://shizune.co/investors/profile/cleantech-open) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Scottish Enterprise](https://shizune.co/investors/profile/scottish-enterprise) — VC Fund
- [Foundation for Innovation and Technology (FIT)](https://shizune.co/investors/profile/foundation-pour-l-innovation-technologique) — VC Fund
- [Business Finland](https://shizune.co/investors/profile/tekes) — VC Fund

## FAQ

### What does NJEDA invest in?

NJEDA invests primarily in Health Care, Biotechnology and Medical startups, most often at Grant and Seed stage. Most of the 142 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact NJEDA?

Public channels for NJEDA include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at NJEDA?

The team at NJEDA includes Frederick J. Cole (Senior Vice President- Operations), Lori Matheus (Senior Vice President- Finance & Development) and Debbie Hart (Chair at the Commission on Science, Innovation and Technology (CSIT)), among 12 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co